The record
| Class | neuroprotective |
|---|---|
| Also known as | Carnosine, Beta-alanyl-L-histidine |
| Chain length | - |
| Molecular weight | 226.23 Da |
| Half-life | Very short in serum (minutes, degraded by carnosinase) |
| Route | Oral, SC, or IM |
| Studied for | - |
| Research use | Neuroprotection studies; Anti-aging research; Exercise performance |
| What has been shown | Intracellular pH buffering; Metal chelation (Cu, Zn); Anti-glycation activity; Antioxidant properties |
| How it works | Endogenous dipeptide found abundantly in muscle and brain tissue. Functions as intracellular buffer (histidine imidazole ring), antioxidant (metal chelation, ROS scavenging), anti-glycation agent, and neuroprotectant. Degraded by carnosinase (CN1) in serum. |
| Patent status | Generic (natural dipeptide) |
| Regulatory status | Dietary supplement / Research |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Nerve Support / Neuro-repair Environment (affection, 46%)
- Neuroprotection Signaling (affection, 63%)
- Oxidative Stress Resilience (affection, 80%)
- Acetaminophen toxicity (illness, 60%)
- Age-related macular degeneration (illness, 40%)
- Age-related vascular decline (illness, 30%)
- Antioxidant supplementation (illness, 60%)
- Atherosclerosis (illness, 30%)
- Barth syndrome (illness, 40%)
- Circadian rhythm disorders (illness, 40%)
- Cognitive decline (illness, 40%)
- Detoxification support (illness, 60%)
- Erythropoietic protoporphyria - FDA approved (illness, 30%)
- Heart failure (illness, 40%)
- Memory impairment (illness, 40%)
- Microcirculation disorders (illness, 30%)
- Mitochondrial myopathies (illness, 40%)
- Neuroprotection (illness, 40%)
- Polymorphous light eruption (illness, 30%)
- Skin lightening (illness, 60%)
- Solar urticaria (illness, 30%)
- Vascular dysfunction (illness, 30%)
- Vitiligo (illness, 30%)
- Fatigue or low energy (symptom, 33%)